ChromaDex Company
ChromaDex has developed a proprietary form of nicotinamide riboside (NR), a metabolic precursor of NAD+, which is a critical part of cellular functioning that declines with age. The company has conducted human clinical trials of its compound, showing that it increases NAD+ levels in humans, and it has been found to be safe by the FDA.
Headquarters:
United States
Employee Number:
101-250
Founded Date:
1999
Investment Stage:
N/A
Technology:
Cancer
Estimated Revenue:
$10M to $50M
Investor Type:
N/A
Number Of Exists:
N/A
Industry:
Longevity
Funding Status:
IPO